CN110279648A - A kind of cosmetic formulation and purposes of the body containing excretion - Google Patents
A kind of cosmetic formulation and purposes of the body containing excretion Download PDFInfo
- Publication number
- CN110279648A CN110279648A CN201910553007.9A CN201910553007A CN110279648A CN 110279648 A CN110279648 A CN 110279648A CN 201910553007 A CN201910553007 A CN 201910553007A CN 110279648 A CN110279648 A CN 110279648A
- Authority
- CN
- China
- Prior art keywords
- excretion
- adipose
- cosmetic formulation
- stem cell
- seed extract
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9794—Liliopsida [monocotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/99—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from microorganisms other than algae or fungi, e.g. protozoa or bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/74—Biological properties of particular ingredients
- A61K2800/78—Enzyme modulators, e.g. Enzyme agonists
- A61K2800/782—Enzyme inhibitors; Enzyme antagonists
Abstract
The invention discloses a kind of cosmetic formulations of body containing excretion, include adipose-derived mescenchymal stem cell excretion body.Adipose-derived mescenchymal stem cell excretion body is added in the cosmetic formulation of the body containing excretion of the present invention, adipose-derived mescenchymal stem cell excretion body has the activity for inhibiting elastoser and Collagenase, it is effective against aging, improves the elasticity of skin, improves wrinkle of skin；It is used cooperatively with lightening compositions, moreover it is possible to which the effect of the compact skin of better whitening is played in the absorption for promoting lightening compositions.
Description
Technical field
The present invention relates to a kind of stem cell excretion bodies and application thereof, and in particular to a kind of cosmetic formulation and use of the body containing excretion
On the way.
Background technique
Excretion body (Exosome) is by intracellular vesicles structure release to a kind of extracellular film property vesica, diameter about 30-
150nm, cell can all secrete excretion body under normal physiological status, due to merging between plasma membrane and multivesicular body as a result, outer
It secretes body sample vesica and external space of cell is secreted by exocytosis.Excretion body sample vesica be divided by double-layer of lipoid it is inside and outside,
Since it contains membrane lipid, memebrane protein, inhereditary material and cytoplasmic components, reflect the property and state of cell indirectly.Together
When, excretion body sample vesica by and other cells and tissue combination, and by film component, mRNA, miRNA, protein (growth swash
Element, cell factor etc.) etc. be transferred to recipient cell, and as the extracellular transport protein communicated between mediate cell-cell.
Skin aging is the damage collective effect such as the intrinsic physiological mechanism of human senility and extraneous exposing to the weather, environmental pollution
Result.Skin aging is usually embodied in the generation of skin elasticity reduction and wrinkle of skin, it was reported that collagen and elastic egg
White reduction will lead to skin elasticity reduction and wrinkle of skin generates, and collagen and elastin laminin are by Collagenase and elasticity
Protease regulator, Collagenase and elastoser can cause collagen and elastin degradation, so as to cause collagen
Albumen and elastin laminin are reduced, and wrinkle is caused to generate, and skin elasticity lowers.There has been no to adipose-derived mescenchymal stem cell at present
Correlative study of the excretion body in terms of skin anti-aging.
Summary of the invention
A kind of beauty system of body containing excretion is provided it is an object of the invention to overcome the shortcomings of the prior art place
Agent and purposes.
To achieve the above object, the technical scheme adopted by the invention is as follows: a kind of cosmetic formulation of the body containing excretion, comprising fat
Derived mesenchymal stem cell excretion body.Adipose-derived mescenchymal stem cell excretion body, which has, inhibits elastoser and collagen
The activity of enzyme, is effective against aging, improves the elasticity of skin, improves wrinkle of skin.
Preferably, the cosmetic formulation also includes lightening compositions；The lightening compositions include Katsumadai seed extract, apricot
Benevolence extract and jasmine flower extract.
It is Zingiber Alpinia perennial herb spice berry in one's early teens, Katsumadai seed extract can effectively inhibit golden yellow grape
The growth of the bacteriums such as coccus, staphylococcus epidermis, Escherichia coli, while the generation that Katsumadai seed extract covers memebrane protein to people has
Facilitation, people, which covers memebrane protein, can promote the formation of keratin membrane albumen, improve the barrier function of skin.Katsumadai seed extract
In contain fanesol, phellandrene and Flavonoid substances, there is good inhibiting effect to the activity of TYR enzyme, can be from source
The generation of melanin is reduced on head, and there is the effect of whitening and light spot.
Apricot seed extract contains citric acid, malic acid, amygdalin, fatty acid etc., is furthermore especially enriched in calcium and phosphorus, also contains
Saccharic, calcium, sodium, cellulosic, vitamin A, B, C etc., to be coarse, dry skin provides moisturizing and nutrition.In addition, fatty acid
Keratoderma can be made to soften, moistening skin-care, and can press down it is bactericidal, in addition, apricot seed extract is able to suppress tyrosine in skin
The activity of enzyme, removes potential spot, and even skin tone has light spot skin lightening effect.
Jasmine flower extract, can moisturize fragrant flesh with long hair, and the substances such as the essential oil contained, linalool rouge are able to suppress skin
Colour of skin element forms while activating epidermal cell, is conducive to the regeneration of skin.
Cosmetic formulation of the present invention extracts adipose-derived mescenchymal stem cell excretion body and Katsumadai seed extract, almond
Object and jasmine flower extract are used cooperatively, and skin elasticity can be improved, while slowing down wrinkle, moreover it is possible to promote the suction of lightening compositions
It receives, plays the effect of the compact skin of better whitening.
Preferably, the weight ratio of adipose-derived the mescenchymal stem cell excretion body and lightening compositions are as follows: 1~3:1.
When the two uses said ratio, skin assimilation effect is preferable, and whitening effect is more significant.
It is highly preferred that the weight ratio of adipose-derived the mescenchymal stem cell excretion body and lightening compositions are as follows: 2:1.
When in particular by said ratio, whitening effect is best.
Preferably, the weight ratio of the Katsumadai seed extract, apricot seed extract and jasmine flower extract are as follows: mention in one's early teens
Take object: apricot seed extract: jasmine flower extract=1~3:4:1~3.When each extract uses said ratio, TYR enzyme inhibits
Better effect.
It is highly preferred that the weight ratio of the Katsumadai seed extract, apricot seed extract and jasmine flower extract are as follows: in one's early teens
Extract: apricot seed extract: jasmine flower extract=1:2:1.When in particular by said ratio, TYR enzyme inhibitory effect is most
It is good.
Preferably, the adipose-derived mescenchymal stem cell excretion body preparation method the following steps are included:
(1) it disperses adipose tissue in digestive juice, obtains cell suspending liquid；
(2) by cell suspending liquid centrifugal treating, liquid is discarded supernatant, obtains fat stem cell；
(3) fat stem cell is seeded to culture medium and carries out amplification cultivation, centrifugation takes supernatant, is concentrated, and excretion body is added
Extractant obtains the adipose-derived mescenchymal stem cell excretion body.
For the adipose tissue-derived in human or animal, it is Exoquick-TC (SBI) that the excretion body, which extracts reagent, can also
Think that the excretion body of other brands extracts reagent.There is CD9, CD63 mark in the adipose-derived mescenchymal stem cell excretion body
Will.
Preferably, in step (1), the digestive juice is the PBS buffer solution containing collagenase type I；The collagenase type I
Volume is the 0.2~0.4% of adipose tissue volume, and the additional amount of the PBS buffer solution is 4~6 times of adipose tissue volume, is disappeared
The change time is 45~90min；
In step (3), the condition of the amplification cultivation are as follows: in incubator, under the conditions of 36~38 DEG C, 5%CO2, culture medium
For the DMEM culture medium containing 10%FBS, incubation time is 48~72h.
Preferably, in step (2), the revolving speed of the centrifugation is 1800~2200r/min, and the time is 3~5min.
Preferably, in step (3), after excretion body extractant is added, 8~15h is placed at 3~5 DEG C, is then centrifuged for, takes
Precipitating, i.e., the described adipose-derived mescenchymal stem cell excretion body.
Preferably, the cosmetic formulation is aqua, emulsion, cream, gel or pulvis.Except said components clearly require
Outside, in the range of lossless effect of the invention, those skilled in the art can add according to the dosage form of specific cosmetic formulation
Or use other adjunct ingredients.
Preferably, in the cosmetic formulation, the weight percentage of adipose-derived mescenchymal stem cell excretion body is 0.1~
1%.
The object of the invention is also to provide the cosmetic formulations of the body containing excretion to inhibit TYR enzyme preparation, whitening system
Agent inhibits elastin laminin enzyme preparation, inhibits the use in collagenase preparation, anti-senile preparation or improvement skin elasticity preparation
On the way.
The beneficial effects of the present invention are: the present invention provides a kind of cosmetic formulation of body containing excretion, the cosmetic formulations
In be added to adipose-derived mescenchymal stem cell excretion body, adipose-derived mescenchymal stem cell excretion body, which has, inhibits elastin laminin
The activity of enzyme and Collagenase, is effective against aging, improves the elasticity of skin, improves wrinkle of skin；By itself and whitening group
It closes object to be used cooperatively, moreover it is possible to which the effect of the compact skin of better whitening is played in the absorption for promoting lightening compositions.
Detailed description of the invention
Fig. 1 is the active testing result of elastoser.
Specific embodiment
Each raw material in embodiment in addition to fatty derived mesenchymal stem cell excretion body is purchased from market.
To better illustrate the object, technical solutions and advantages of the present invention, below in conjunction with specific embodiment to the present invention
It is described further.
Embodiment 1
A kind of embodiment of the cosmetic formulation of the body of the present invention containing excretion, the beauty system of the body containing excretion described in the present embodiment
Agent includes the component of following weight percentage: adipose-derived mescenchymal stem cell excretion body 0.8%, Katsumadai seed extract
0.1%, apricot seed extract 0.2%, jasmine flower extract 0.1%, SIMMONDSIA CHINENSIS SEED OIL 10%, glycerol 10%, propylene glycol 3%, transparent
Matter acid 0.5%, PEG-20 methyl sesquistearate 2%, methyl glucoside sesquistearate 1%, carbomer
0.3%, methylparaben 0.1%, the deionized water of Phenoxyethanol 0.4% and surplus.
The preparation method of adipose-derived mescenchymal stem cell excretion body described in the present embodiment the following steps are included:
(1) it disperses human fat tissue in the PBS buffer solution digestive juice containing collagenase type I, the collagenase type I
Volume is the 0.3% of adipose tissue volume, and the additional amount of the PBS buffer solution is 5 times of adipose tissue volume, and digestion time is
60min obtains cell suspending liquid；
(2) cell suspending liquid is discarded supernatant liquid, obtains fat stem cell in 2000r/min centrifugal treating 4min；
(3) fat stem cell is seeded to culture medium and carries out amplification cultivation, the condition of the amplification cultivation are as follows: in incubator
It is interior, under the conditions of 36~38 DEG C, 5%CO2, culture medium is the DMEM culture medium containing 10%FBS, and incubation time is 72h centrifugation, is taken
Clear liquid is concentrated into 50% or more volume-diminished, is added excretion body extractant Exoquick-TC (SBI), and excretion body extractant adds
Entering amount is the supernatant after concentration 50% to get the adipose-derived mescenchymal stem cell excretion body.
Embodiment 2
One, elastase inhibitory activity
Substrate N- succinyl-alanine-alanine-alanine-p- nitro is acted on by pancreatic elastase by measuring
The amount of 4- nitroaniline (4-nitoanilide) peptide fragment that aniline generates utilizes the work of spectrophotometry assessment elastoser
Property.N- succinyl-alanine-alanine-alanine-p-NA Sigma) and it is other for test substance at 37 DEG C
The reaction of porcine pancreatic elastase initial is added in lower incubation.Measurement wavelength be 410nm place absorbance come measure be released dissociate
The amount of 4- nitroaniline.The Tris-HCl buffer that the pH of 0.2M is 8.0 is used as negative control, lightening compositions (mass concentration
For 0.1% Katsumadai seed extract, the mixture of 0.2% apricot seed extract and 0.1% jasmine flower extract) as a control group.It is real
Apply adipose-derived mescenchymal stem cell excretion body made from example 1 analysis matrix in ultimate density be 0.05%, 0.1%,
0.3%, 0.8%, 1% and 1.2%.Test result is shown in Fig. 1.It is relatively negative right from Fig. 1 elastase enzyme suppression percentage
According to percentage, it will be seen from figure 1 that adipose-derived mescenchymal stem cell excretion body to elastase activity have dosage according to
Rely formula inhibitory effect, and lightening compositions are unobvious to the inhibitory effect of elastase activity.
Two, Collagenase inhibition analysis
Collagenase (enzyme EC 3.4.24.3,5 μ g) individually with adipose-derived mescenchymal stem cell excretion body (1 μ g/mL
It is added to together in the Tris buffer (pH=7.4) of the 0.1M containing PZ peptide (0.5mg) respectively with 10 μ g/mL), makes total volume
For 1.7ml, PZ peptide is the substrate of Collagenase.Mixture incubates 30min in 37 DEG C of water-baths, and the 25mM of 1mL is then added
Citric acid solution terminate enzyme reaction.After the ethyl acetate mixing of 5mL is added, it is in wavelength using ultraviolet specrophotometer
The absorbance of organic layer is measured at 320nm.Collagenase inhibition is calculated by following formula:
Collagenase suppression percentage=[(Ac-As)/Ac] × 100, wherein Ac expression (contains Collagenase
The absorbance of control of the absorbance-of control without Collagenase), As indicates the (extinction of the sample containing Collagenase
The absorbance of sample of the degree-without Collagenase).
Compared with the control, the Collagenase of 0.1% and 1.0% adipose-derived mescenchymal stem cell excretion body inhibits hundred
Point than being respectively 88.5% and 62.8%, collagen enzyme inhibition activity is shown, and (mass concentration is lightening compositions
The mixture of 0.1% Katsumadai seed extract, 0.2% apricot seed extract and 0.1% jasmine flower extract) Collagenase inhibit
Percentage is 94.1%, shows that lightening compositions are unobvious to the inhibitory effect of Collagenase.
Three, tyrosinase inhibition analysis
Tyrosinase catalysis substrate DOPA generates DOPA quinone, and further oxidation generates melanin, and melanin is in 475nm wave
With maximum absorption band.By the way that in the analytical unit time, enzymic catalytic reaction system generates the growth straight line of melanin variable quantity, with
Straight slope measures enzyme activity size.Enzyme activity unit (U) is defined as: absorbance of the melanin per minute in 475nm wavelength
(OD475) increase by 0.001 as an enzyme activity unit.
Tyrosinase activity method for measuring of the invention: reaction total system is 3mL, the phosphate buffer solution of addition
0.2mL tyrosinase aqueous solution is added in 2.4mL, and 10min is kept the temperature in 32 DEG C of thermostat water baths, and L-DOPA solution 0.4mL is added
OD when being placed in test tube, and measuring 10min475.According to the definition of activity of enzyme reaction, in the presence of having inhibitor, activity of enzyme reaction
It is expressed as ACTi；In the presence of no inhibitor, activity of enzyme reaction is then expressed as ACT0, then sample to be tested is to the opposite of tyrosinase
Inhibiting rate (I) can be with is defined as:
I (%)=(1-ACTi/ACT0) × 100%=[1- (OD1-OD3)/(OD2-OD4)] × 100%
In formula: OD1Refer to the absorbance value of the live body system containing substrate, tyrosinase, sample to be tested；
OD2Refer to the absorbance value for containing only substrate, tyrosinase activity measurement system；
OD3Refer to the absorbance value for containing only substrate, sample to be tested determination of activity system；
OD4Refer to the absorbance value for containing only substrate, buffer solution determination of activity system.
Test group 1~3 is subjected to external tyrosinase activity measurement and as a control group with deionized water uses ultraviolet point
Light photometric determination sample tyrosinase activity, the results are shown in Table 1.
1 tyrosinase activity test result of table
As it can be seen from table 1 lightening compositions have certain external tyrosinase activity inhibitory effect, adipose-derived is filled
The tyrosinase activity inhibitory effect of matter stem cell excretion body is not significant.
Using same method, but the Katsumadai seed extract of different ratio, apricot seed extract, Jasmine identical to concentration are mentioned
It takes object to carry out external tyrosinase activity and inhibits test, test result shows Katsumadai seed extract, apricot seed extract and jasmine
The weight ratio of flower extract are as follows: Katsumadai seed extract: apricot seed extract: junket ammonia when jasmine flower extract=1~3:4:1~3
Phytase activity inhibitory effect is preferable, especially the weight ratio of Katsumadai seed extract, apricot seed extract and jasmine flower extract are as follows:
Katsumadai seed extract: apricot seed extract: inhibitory effect is best when jasmine flower extract=1:2:1.
Four, in order to verify adipose-derived mescenchymal stem cell excretion body to the facilitation effect of lightening compositions, foundation " is made up
Product hygienic practice " (version in 2007) tested.Select 30 healths, the volunteer without cosmetic allergic contact dermatitis history, every group 10
Name (men and women is unlimited) uses the skin care item of test group 4~6 after the daily morning and evening face cleaning of volunteer respectively, carries out dermal melanin
Detection, the formula of the skin care item of test group 4~6 is respectively as follows:
Test group 4: adipose-derived mescenchymal stem cell excretion body 1.2%, SIMMONDSIA CHINENSIS SEED OIL 10%, glycerol 10%, propylene glycol
3%, hyaluronic acid 0.5%, PEG-20 methyl sesquistearate 2%, methyl glucoside sesquistearate 1%,
Carbomer 0.3%, methylparaben 0.1%, the deionized water of Phenoxyethanol 0.4% and surplus.
Test group 5: Katsumadai seed extract 0.3%, apricot seed extract 0.6%, jasmine flower extract 0.3%, SIMMONDSIA CHINENSIS SEED OIL
10%, glycerol 10%, propylene glycol 3%, hyaluronic acid 0.5%, PEG-20 methyl sesquistearate 2%, methyl glucose
Glucosides sesquistearate 1%, carbomer 0.3%, methylparaben 0.1%, Phenoxyethanol 0.4% and surplus deionization
Water.
Test group 6: cosmetic formulation described in embodiment 1.
Testing result is shown in Table 2.
The testing result of 2 dermal melanin of table
| Group | 0 week | 2 weeks | 4 weeks | 6 weeks | 8 weeks |
| Test group 4 | 100% | 97% | 96% | 95% | 95% |
| Test group 5 | 100% | 92% | 89% | 85% | 80% |
| Test group 6 | 100% | 90% | 86% | 83% | 76% |
From table 2 it can be seen that in adipose-derived mescenchymal stem cell excretion body, Katsumadai seed extract, apricot seed extract, jasmine
Under jasmine flower extract total addition level unanimous circumstances, the whitening effect using skin care item described in test group 6 is more significant, illustrates rouge
Fat derived mesenchymal stem cell excretion body can promote absorption of the skin to lightening compositions, to play synergy
Whitening effect.
Using the above method to adipose-derived mescenchymal stem cell excretion body, Katsumadai seed extract, apricot seed extract and jasmine
The total addition level of jasmine flower extract is identical, but is tested when different ratio, research shows that when adipose-derived mesenchyma is dry
When the weight ratio of cell excretion body and lightening compositions is 1~3:1, there can be preferable whitening effect, and adipose-derived is filled
The weight ratio of matter stem cell excretion body and lightening compositions is best when being 2:1.When adipose-derived mescenchymal stem cell excretion body
Additive amount be 0.1~1% when, preferable whitening facilitation effect can be realized.
Finally, it should be noted that the above embodiments are merely illustrative of the technical solutions of the present invention rather than protects to the present invention
The limitation of range is protected, although the invention is described in detail with reference to the preferred embodiments, those skilled in the art should
Understand, it can be with modification or equivalent replacement of the technical solution of the present invention are made, without departing from the essence of technical solution of the present invention
And range.
Claims (10)
1. a kind of cosmetic formulation of body containing excretion, which is characterized in that include adipose-derived mescenchymal stem cell excretion body.
2. the cosmetic formulation of the body containing excretion as described in claim 1, which is characterized in that the cosmetic formulation also includes whitening combination
Object；The lightening compositions include Katsumadai seed extract, apricot seed extract and jasmine flower extract.
3. the cosmetic formulation of the body containing excretion as claimed in claim 2, which is characterized in that outside the adipose-derived mescenchymal stem cell
Secrete the weight ratio of body and lightening compositions are as follows: 1~3:1；Preferably, the adipose-derived mescenchymal stem cell excretion body and beauty
The weight ratio of white composition are as follows: 2:1.
4. the cosmetic formulation of the body containing excretion as claimed in claim 2, which is characterized in that the Katsumadai seed extract, almond extract
The weight ratio of object and jasmine flower extract are as follows: Katsumadai seed extract: apricot seed extract: jasmine flower extract=1~3:4:1~
3；Preferably, the weight ratio of the Katsumadai seed extract, apricot seed extract and jasmine flower extract are as follows: Katsumadai seed extract:
Apricot seed extract: jasmine flower extract=1:2:1.
5. the cosmetic formulation of the body containing excretion as described in claim 1, which is characterized in that outside the adipose-derived mescenchymal stem cell
Secrete the preparation method of body the following steps are included:
(1) it disperses adipose tissue in digestive juice, obtains cell suspending liquid；
(2) by cell suspending liquid centrifugal treating, liquid is discarded supernatant, obtains fat stem cell；
(3) fat stem cell is seeded to culture medium and carries out amplification cultivation, centrifugation takes supernatant, is concentrated, and excretion body is added and extracts
Agent obtains the adipose-derived mescenchymal stem cell excretion body.
6. the cosmetic formulation of the body containing excretion as claimed in claim 5, which is characterized in that in step (1), the digestive juice be containing
The PBS buffer solution of collagenase type I；The volume of the collagenase type I is the 0.2~0.4% of adipose tissue volume, and the PBS is slow
The additional amount of fliud flushing is 4~6 times of adipose tissue volume, and digestion time is 45~90min；
In step (3), the condition of the amplification cultivation are as follows: in incubator, under the conditions of 36~38 DEG C, 5%CO2, culture medium be containing
The DMEM culture medium of 10%FBS, incubation time are 48~72h.
7. the cosmetic formulation of the body containing excretion as claimed in claim 2, which is characterized in that in step (3), excretion body extractant is added
Afterwards, 8~15h is placed at 3~5 DEG C, is then centrifuged for, is taken precipitating, i.e., the described adipose-derived mescenchymal stem cell excretion body.
8. the cosmetic formulation of the body containing excretion as described in any one of claim 1~7, which is characterized in that the cosmetic formulation is
Aqua, emulsion, cream, gel or pulvis.
9. the cosmetic formulation of the body containing excretion as described in claim 1, which is characterized in that in the cosmetic formulation, adipose-derived
The weight percentage of mesenchymal stem cells excretion body is 0.1~1%.
10. the cosmetic formulation of the body containing excretion is inhibiting TYR enzyme preparation, whitening system as described in any one of claim 1~9
Agent inhibits elastin laminin enzyme preparation, inhibits the use in collagenase preparation, anti-senile preparation or improvement skin elasticity preparation
On the way.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910553007.9A CN110279648A (en) | 2019-06-24 | 2019-06-24 | A kind of cosmetic formulation and purposes of the body containing excretion |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910553007.9A CN110279648A (en) | 2019-06-24 | 2019-06-24 | A kind of cosmetic formulation and purposes of the body containing excretion |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN110279648A true CN110279648A (en) | 2019-09-27 |
Family
ID=68005632
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910553007.9A Pending CN110279648A (en) | 2019-06-24 | 2019-06-24 | A kind of cosmetic formulation and purposes of the body containing excretion |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110279648A (en) |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111544577A (en) * | 2020-05-27 | 2020-08-18 | 和携科技有限公司 | Female reproduction nursing preparation and preparation method thereof |
| CN111632069A (en) * | 2020-06-17 | 2020-09-08 | 北京中瑞联合生物科技有限公司 | Medicine for improving skin condition and preparation method and application thereof |
| WO2021104214A1 (en) * | 2019-11-27 | 2021-06-03 | 沣潮医药科技（上海）有限公司 | Use of exosome derived from carcass in skin regulation product |
| CN113171411A (en) * | 2021-04-28 | 2021-07-27 | 奥启(深圳)创投科技有限公司 | Composition containing adipose-derived stem cell exosomes with whitening function |
| CN113288855A (en) * | 2021-04-09 | 2021-08-24 | 深圳市莱利赛生物科技有限公司 | Beauty fluid based on adipose-derived stem cell exosomes and preparation method and application thereof |
| CN113893216A (en) * | 2021-10-14 | 2022-01-07 | 安徽中美生谷生物科技有限公司 | Composition with whitening effect and preparation method thereof |
| CN114081861A (en) * | 2021-11-19 | 2022-02-25 | 和泓尚医(成都)生物科技有限公司 | Stem cell exosome and compound peptide anti-aging preparation as well as preparation method and application thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106880646A (en) * | 2017-03-30 | 2017-06-23 | 山东大学 | Application of the adipose-derived mescenchymal stem cell excretion body in treatment antiobesity agents are prepared |
| CN109620749A (en) * | 2019-02-27 | 2019-04-16 | 嘉文丽（福建）化妆品有限公司 | The preparation method of stem cell composition and extract containing fat mesenchymal stem cell excretion protein extract and the application of composition |
-
2019
- 2019-06-24 CN CN201910553007.9A patent/CN110279648A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106880646A (en) * | 2017-03-30 | 2017-06-23 | 山东大学 | Application of the adipose-derived mescenchymal stem cell excretion body in treatment antiobesity agents are prepared |
| CN109620749A (en) * | 2019-02-27 | 2019-04-16 | 嘉文丽（福建）化妆品有限公司 | The preparation method of stem cell composition and extract containing fat mesenchymal stem cell excretion protein extract and the application of composition |
Non-Patent Citations (2)
| Title |
|---|
| 国家食品药品监督管理局: ""化妆品禁用组分（表1）"", 《化妆品安全技术规范》 * |
| 王建新: "《化妆品植物原料大全》", 30 June 2012, 中国纺织出版社 * |
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021104214A1 (en) * | 2019-11-27 | 2021-06-03 | 沣潮医药科技（上海）有限公司 | Use of exosome derived from carcass in skin regulation product |
| CN111544577A (en) * | 2020-05-27 | 2020-08-18 | 和携科技有限公司 | Female reproduction nursing preparation and preparation method thereof |
| CN111544577B (en) * | 2020-05-27 | 2022-11-04 | 和携科技有限公司 | Female reproduction nursing preparation and preparation method thereof |
| CN111632069A (en) * | 2020-06-17 | 2020-09-08 | 北京中瑞联合生物科技有限公司 | Medicine for improving skin condition and preparation method and application thereof |
| CN113288855A (en) * | 2021-04-09 | 2021-08-24 | 深圳市莱利赛生物科技有限公司 | Beauty fluid based on adipose-derived stem cell exosomes and preparation method and application thereof |
| CN113171411A (en) * | 2021-04-28 | 2021-07-27 | 奥启(深圳)创投科技有限公司 | Composition containing adipose-derived stem cell exosomes with whitening function |
| CN113893216A (en) * | 2021-10-14 | 2022-01-07 | 安徽中美生谷生物科技有限公司 | Composition with whitening effect and preparation method thereof |
| CN114081861A (en) * | 2021-11-19 | 2022-02-25 | 和泓尚医(成都)生物科技有限公司 | Stem cell exosome and compound peptide anti-aging preparation as well as preparation method and application thereof |
| CN114081861B (en) * | 2021-11-19 | 2023-10-31 | 和泓尚医(成都)生物科技有限公司 | Stem cell exosome and compound peptide anti-aging preparation and preparation method and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN110279648A (en) | A kind of cosmetic formulation and purposes of the body containing excretion | |
| CN103520014B (en) | Dermatologic preparation composition containing the Ginsenoside F2 from hydroponic culture ginseng | |
| CN103479538B (en) | The Dermatologic preparation composition of the flower containing Radix Ginseng or the seed extract of Radix Ginseng | |
| CN110151678A (en) | It is a kind of for improving the composition and cosmetics comprising source of human stem cell excretion body of wrinkle | |
| CN103037880B (en) | The compositions of the extract containing Broussonetia papyrifera | |
| US8808761B2 (en) | Composition of skin external application containing rose extract and epigallocatechin gallate(EGCG) | |
| KR101928797B1 (en) | Composition of skin external application containing compound K | |
| KR101972071B1 (en) | Cosmetic composition for improving skin tone or skin elasticity | |
| CN109453087B (en) | Whitening skin-penetrating lotion, preparation method thereof and whitening cosmetic additive | |
| CN102421412B (en) | Composition containing chamaecyparis obtusa polysaccharides to be externally applied to skin | |
| CN110430865A (en) | Cosmetic composition and application thereof comprising Inonotus obliquus extract | |
| KR101825803B1 (en) | Cosmetic Anti aging composition of mountain-ash's ferment | |
| US10149817B2 (en) | Topical skin treatment composition comprising dendranthema indicum extract | |
| KR102286679B1 (en) | External composition for skin containing an enzyme-treated saponin fraction derived from the root of Camellia sinensis | |
| JP2023171950A (en) | Anti-aging agent, antioxidant, anti-inflammatory agent, and whitening agent, as well as cosmetic | |
| KR101449282B1 (en) | Composition for improving skin wrinkle and skin moisturing comprising Barley fermented by Pichia jadinii and Aureobasidium pullulans bacteria | |
| KR20120021709A (en) | Cosmetic composition containing flavonoid derivatives | |
| KR20080061080A (en) | Cosmetic composition comprising tuber melanosporum | |
| CN111110581A (en) | Novel agaro-oligosaccharide composition with whitening function improving function and application thereof | |
| CN116549322A (en) | Plasmin composition with whitening and freckle removing effects and application thereof | |
| KR101172058B1 (en) | A composition for skin external application for improving skin wrinkle and enhancing elasticity | |
| KR101939112B1 (en) | Composition of skin external application containing ginsenoside F1 | |
| KR101909533B1 (en) | Composition of skin external application containing ginsenoside F1 | |
| KR101939111B1 (en) | Composition of skin external application containing ginsenoside F2 | |
| KR100585613B1 (en) | External application composition containing ?-1,3-glucan and ginseng saponin |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20190927 |